Troy Robert Torgerson MD
Assistant Professor of Pediatrics at the University of Washington
Join to View Full Profile
4800 Sand Point Way NESeattle, WA 98105
Phone+1 206-987-7450
Dr. Torgerson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Pediatric Rheumatology, 2001 - 2004- University of WashingtonResidency, Pediatrics, 1998 - 2001
Vanderbilt University School of MedicineClass of 1998
Certifications & Licensure
WA State Medical License 2000 - 2025
Publications & Presentations
PubMed
- Hallmarks of terminal T-cell exhaustion are absent in multiple myeloma from diagnosis through maintenance therapy.Carolyn Shasha, David R Glass, Ernest Moelhman, Laura Islas, Yuan Tian
Blood. 2025-03-31 - Provide proactive reproducible analysis transparency with every publication.Paul Meijer, Nicole Howard, Jessica Liang, Autumn Kelsey, Sathya Subramanian
Royal Society Open Science. 2025-03-01 - Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells.Christopher D Thouvenel, Christopher M Tipton, Yasuhiro Yamazaki, Ting-Ting Zhang, Stacey Rylaarsdam
Journal of Clinical Immunology. 2025-01-15
Press Mentions
- Inflammation Firestorm Could Be the Secret Culprit of Long COVIDJune 13th, 2023
- Researchers Identify Type of Long COVID with Persistent InflammationJune 18th, 2023
- Long-Covid Patients Suffer from Persistent Inflammation: Study | HealthJune 18th, 2023
- Join now to see all
Grant Support
- Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunityUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunityUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunityUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutationsBAYLOR COLLEGE OF MEDICINE2021–2027
- Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutationsBAYLOR COLLEGE OF MEDICINE2021–2027
- Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutationsBAYLOR COLLEGE OF MEDICINE2021–2027
- Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and ImmunizationSEATTLE CHILDREN'S HOSPITAL2017–2027
- Curation of genetic defects causing combined immunodeficiency and infections in childrenBAYLOR COLLEGE OF MEDICINE2021–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
